Literature DB >> 19712200

Hepatic epithelioid haemangioendothelioma: challenges in diagnosis and management.

L W Y Thin1, D D Wong, B W De Boer, J M Ferguson, L Adams, G Macquillan, L Delriviere, A Mitchell, G P Jeffrey.   

Abstract

BACKGROUND: Hepatic epithelioid haemangioendothelioma (HEH) is a rare, low grade malignant neoplasm of endothelial origin which is difficult to diagnose and has a variable outcome. We review five HEH cases from our centre with the aim of identifying clinical predictors of outcome and various therapeutic options.
METHODS: A search was made on the WA Liver Transplant registry for cases with histologically confirmed HEH. Their medical records were reviewed. A literature search was conducted through Medline using terms to compare the results from this series with those of other series.
RESULTS: Five patients were identified to have HEH. The mean age was 44.2years (range 34-53years). Four of five patients presented with dyspepsia and two patients had clinical evidence of portal hypertension with ascites. Two patients had radiologically diffuse disease and three patients had discrete nodular liver involvement. The mean duration from presentation of symptoms to diagnosis of HEH was 26.8months. Liver transplantation was performed in one patient with diffuse HEH who is alive with no disease recurrence at 3years. Three patients with radiologically stable disease followed with 6monthly surveillance imaging are currently alive and well. The median survival of all five patients was 5years (range 1.5-16years) at the time of follow up.
CONCLUSIONS: These results support the role of surveillance alone for patients with focal and radiologically stable disease. Patients with diffuse HEH with hepatic decompensation should be considered for transplantation. However, numbers are small and an international registry is required to make firm comparisons.
© 2010 The Authors. Internal Medicine Journal © 2010 Royal Australasian College of Physicians.

Entities:  

Mesh:

Year:  2010        PMID: 19712200     DOI: 10.1111/j.1445-5994.2009.02043.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  5 in total

1.  Hepatic Epithelioid Hemangioendothelioma - a Rare Tumor and Diagnostic Dilemma.

Authors:  Vladislav Treska; Ondrej Daum; Martin Svajdler; Vaclav Liska; Jiri Ferda; Jan Baxa
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

2.  Metastatic Hepatic Epitheloid Hemangioendothelioma in a Young Male: A Rare Presentation.

Authors:  Tanweerul Huda; Mohammad Masoom Parwez; Bharati Pandya
Journal:  Gastrointest Tumors       Date:  2021-02-18

3.  Eight years tumor control with pazopanib for a metastatic resistant epithelioid hemangioendothelioma.

Authors:  Olivia Bally; Louis Tassy; Bertrand Richioud; Anne-Valérie Decouvelaere; Jean-Yves Blay; Olfa Derbel
Journal:  Clin Sarcoma Res       Date:  2015-04-23

4.  Hepatic epithelioid hemangioendothelioma: Dilemma and challenges in the preoperative diagnosis.

Authors:  Hai-Jie Hu; Yan-Wen Jin; Qiu-Yang Jing; Anuj Shrestha; Nan-Sheng Cheng; Fu-Yu Li
Journal:  World J Gastroenterol       Date:  2016-11-07       Impact factor: 5.742

5.  Hepatic epithelioid hemangioendothelioma: A comparison of Western and Chinese methods with respect to diagnosis, treatment and outcome.

Authors:  Xin Yan Zhao; Mohmedmohsin Ismail Ahmed Rakhda; Sohail Habib; Ali Bihi; Abdullah Muhammad; Tai Ling Wang; Ji-Dong Jia
Journal:  Oncol Lett       Date:  2014-02-03       Impact factor: 2.967

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.